First-Line Crizotinib in ALK-Positive Lung Cancer

被引：0
|
作者：
Tural, Deniz [1 ]
Kilickap, Saadettin [2 ]
机构：
[1] Akdeniz Univ, Sch Med, TR-07058 Antalya, Turkey
[2] Hacettepe Univ, Inst Canc, Ankara, Turkey
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2015年 / 372卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：781 / 781
页数：1
相关论文
共 50 条
  • [31] An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancer
    Riudavets, Mariona
    Planchard, David
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (03) : 291 - 299
  • [32] A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer
    Wang, Wan-Qing
    Xu, Tao
    Zhang, Jing-Jing
    Wang, Yong
    Wang, Yao
    Zhang, Wei
    Zhu, Jian-Guo
    JOURNAL OF THORACIC DISEASE, 2023, 15 (04) : 1935 - 1947
  • [33] Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
    Cui, Shaohua
    Zhao, Yizhuo
    Dong, Lili
    Gu, Aiqin
    Xiong, Liwen
    Qian, Jialin
    Zhang, Wei
    Niu, Yanjie
    Pan, Feng
    Jiang, Liyan
    CANCER MEDICINE, 2016, 5 (06): : 1013 - 1021
  • [34] New drug approval: First-line lorlatinib in advanced ALK-positive non-small cell lung cancer
    Pasquier, Corentin
    Basse, Clemence
    BULLETIN DU CANCER, 2022, 109 (09) : 877 - 878
  • [35] Combination of crizotinib and radiation in the treatment of ALK-positive and cetuximab-resistant lung cancer
    Li, Chunrong
    Huang, Shyhmin
    Walters, Noah
    Armstrong, Eric A.
    Harari, Paul M.
    CANCER RESEARCH, 2014, 74 (19)
  • [36] Ablative Local Therapy Extends The Clinical Benefit Of Crizotinib In Alk-positive Lung Cancer
    Gan, G. N.
    Camidge, D. R.
    Weickhardt, A. J.
    Doebele, R. C.
    Dzingle, W.
    Scheier, B.
    Kavanagh, B. D.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S211 - S211
  • [37] Ablative Local Therapy Extends the Clinical Benefit of Crizotinib in Alk-positive Lung Cancer
    Gan, G. N.
    Camidge, D. R.
    Weickhardt, A. J.
    Doebele, R. C.
    Dzingle, W.
    Scheier, B.
    Kavanagh, B. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S67 - S68
  • [38] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C. -H.
    Han, J. -Y.
    Lee, J. -S.
    Hochmair, M. J.
    Li, J. Y. -C.
    Chang, G. -C.
    Lee, K. H.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, R.
    Kim, D. -W.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S. N.
    Tiseo, M.
    Gupta, N.
    Haney, J.
    Kerstein, D.
    Popat, S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21): : 2027 - 2039
  • [39] The efficacy of dose reduced crizotinib for advanced ALK-positive nonsmall cell lung cancer
    Naito, M.
    Naoki, Y.
    Takata, S.
    Ishii, S.
    Taniguchi, Y.
    Saijo, N.
    Tamiya, A.
    Omachi, N.
    Okishio, K.
    Morita, S.
    Tanaka, A.
    Shiroyama, T.
    Morishita, N.
    Suzuki, H.
    Okamoto, N.
    Hirashima, T.
    Atagi, S.
    ANNALS OF ONCOLOGY, 2017, 28 : 133 - 133
  • [40] Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China
    Yang, X.
    Dong, X.
    Liu, Y.
    Jin, B.
    Wang, J.
    Wang, Y.
    Zhang, Y.
    Zhuo, M.
    Zhao, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S663 - S663
12345